Merck & Company Inc (MRK)vsPropanc Biopharma, Inc. Common Stock (PPCB)
MRK
Merck & Company Inc
$149.52
+2.18%
HEALTHCARE · Cap: $368.89B
PPCB
Propanc Biopharma, Inc. Common Stock
$1.84
-12.80%
HEALTHCARE · Cap: $4.29M
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
PPCB
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$149.52
$64.86 premium
Intrinsic value data unavailable for PPCB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.8x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PPCB
The strongest argument for PPCB centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PPCB
The primary concerns for PPCB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
PPCB carries more volatility with a beta of 3.33 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (44/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Propanc Biopharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?